Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers are seeking the best dose of CABA-201 to treat people with active idiopathic inflammatory myopathy (IIM). The people in this study have IIM, juvenile idiopathic inflammatory myopathy (JIIM), or myositis. With JIIM and some subtypes of IIM, B cells make the body to attack different tissues, causing inflammation and muscle weakness.
Researchers want to find the best dose of [AC-225]RTX-2358 to use safely in people with advanced sarcoma. The people in this study have sarcoma that has come back or keeps growing after treatment.
I-DXd is a type of drug called an antibody-drug conjugate (ADC). ADCs are made of a monoclonal antibody linked to a drug. The antibody binds to a protein on cancer cells called B7-H3, which plays a role in cancer cell growth. It then releases the anti-cancer drug to kill the cancer cell. By destroying these cells, I-DXd may help slow or stop the growth of your cancer.
The purpose of this study is to see if one year of treatment with olaparib is better than observation alone in patients who had pancreatic cancer surgically removed and who have mutations in the BRCA1, BRCA2 or PALB2 genes. Olaparib is a type of anticancer medication called a PARP inhibitor, which may slow down the process cancer cells use to repair their DNA. Cancer cells need to repair their DNA to survive and grow.
Prostate removal (prostatectomy), a treatment for prostate cancer, can cause urinary incontinence (the inability to control the flow of urine). People experience urinary incontinence in the days immediately following surgery, which can reduce quality of life. Most people experience urinary incontinence for several weeks to months after surgery, but it can last longer.
Researchers want to learn if L19IL2 and L19TNF, alone or together, work well to treat melanoma when given with pembrolizumab. The people in this study have melanoma that has metastasized (spread) or is inoperable (cannot be taken out with surgery). Their cancers keep growing even after having immune-boosting therapy.
To learn more about the purpose of this study and to find out who can join, please click here for Substudy 01A or here for Substudy 01C to visit ClinicalTrials.gov for a full clinical trial description.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers want to see if removing only 1 lymph node with cancer prevents melanoma from coming back in that area. The people in this study have melanoma that spread to just 1 lymph node.
Researchers in this study want to find the best dose of STAR0602 to use in people with advanced solid tumors. The people in this study have cancer that is inoperable (cannot be taken out with surgery) or metastatic (has spread). STAR0602 boosts the immune system to stop tumor growth. It is given intravenously (by vein).
